We give you the next issue of the „Postępy Nauk Medycznych” (Progress in Medicine) in July, which is continuation of previous issues related to hematology.

The manuscript entitled “Occurrence of minor histocompatibility antigens’ disparities in allogeneic hematopoietic stem cell transplantation recipients and their HLA-matched siblings” presents the occurrence of immunogenic mHAgs mismatches between a donor and a recipient of allogeneic hematopoietic stem cell transplantation (alloHSCT) from HLA-matched sibling donors in 35 recipients after myeloablative conditioning between 2000 and 2008.

Chronic eosinophilic leukemia expressing the FIP1L1-PDGFRA fusion gene is a rare myeloproliferative neoplasm characterized by the involvement of vitally important organs. The use of imatinib has dramatically changed the prognosis of this disorder with a response rate close to 100%. The authors present a patient with eosinophilic leukemia with a chronic cough as the sole disease symptom. The introduction of imatinib resulted in symptom resolution and eradication of mutation in molecular assay. The high efficacy of low dose of imatinib was confirmed.

The JAK2V617F point mutation occurs in about 50% of patients with myelofibrosis, but its clinical correlates remain unclear. The authors present the results of the large study including 77 patients. They concluded that JAK2 homozygosity correlated with higher white blood cell count and female gender. They found the tendency to higher hemoglobin concentration in this patients subgroup. The correlation between the JAK2 mutation status and overall survival and risk of blast crisis was not demonstrated.

Non-Hodgkin lymphomas comprise a heterogenous group of lymphoid neoplasms occurring mainly in older patient population and characterized by different clinical course. The etiology remains unclear in majority of cases. This review presents the current knowledge about diagnostic difficulties as well as the problem of choosing the appropriate therapeutic management.